Market revenue in 2022 | USD 292.6 million |
Market revenue in 2030 | USD 1,913.4 million |
Growth rate | 26.5% (CAGR from 2022 to 2030) |
Largest segment | Cell therapy |
Fastest growing segment | Gene Therapy |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy |
Key market players worldwide | Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy manufacturing market will help companies and investors design strategic landscapes.
Cell therapy was the largest segment with a revenue share of 57.35% in 2022. Horizon Databook has segmented the Japan cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Owing to the rising demand for gene therapy products and the presence of enthusiastic investors, the Japanese gene therapy sector is considered as one of the emerging markets in the Asia Pacific region. Takara Bio—a Japan-based company—is a major player in cell and gene therapy manufacturing.
Recently in May 2020, the company expanded its Center for Gene and Cell Processing with the construction of a new facility in Shiga, Japan. This facility is dedicated to the manufacturing of cell and gene therapy products. The presence of such companies with expanding manufacturing services is anticipated to fuel growth of the Japanese market.
In addition, several local companies such as Daiichi Sankyo and Takeda Pharmaceuticals are engaged in capitalizing the avenues by undertaking various initiatives such as partnerships and acquisitions. For instance, in April 2020, Daiichi Sankyo entered into a collaboration with Ultragenyx Pharmaceutical Inc. for the use of gene therapy manufacturing technology.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan cell and gene therapy manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Japan cell and gene therapy manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account